Day One Biopharmaceuticals (NASDAQ:DAWN) Given New $40.00 Price Target at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective trimmed by HC Wainwright from $50.00 to $40.00 in a research report report published on Tuesday, Benzinga reports. They currently have a buy rating on the stock.

A number of other equities analysts have also commented on the stock. The Goldman Sachs Group reduced their price target on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a buy rating on the stock in a research report on Tuesday, February 27th. Needham & Company LLC boosted their price target on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a buy rating in a research report on Wednesday, April 24th. JPMorgan Chase & Co. boosted their price target on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an overweight rating in a research report on Monday, April 22nd. Oppenheimer restated a market perform rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, Wedbush restated an outperform rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, April 24th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has an average rating of Moderate Buy and an average price target of $37.67.

Day One Biopharmaceuticals Stock Up 2.9 %

NASDAQ DAWN opened at $17.08 on Tuesday. The stock has a market cap of $1.49 billion, a P/E ratio of -7.18 and a beta of -1.44. The company’s 50-day simple moving average is $15.47 and its 200 day simple moving average is $14.12. Day One Biopharmaceuticals has a twelve month low of $9.67 and a twelve month high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). Research analysts anticipate that Day One Biopharmaceuticals will post -2.67 earnings per share for the current year.

Insider Transactions at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 2,666 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the transaction, the chief financial officer now directly owns 277,754 shares in the company, valued at $4,235,748.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Samuel C. Blackman sold 2,258 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II sold 2,666 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the transaction, the chief financial officer now owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 195,247 shares of company stock worth $3,376,817. Corporate insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several large investors have recently bought and sold shares of DAWN. SG Americas Securities LLC lifted its holdings in Day One Biopharmaceuticals by 58.7% in the third quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock valued at $454,000 after buying an additional 13,683 shares during the period. Bank of New York Mellon Corp lifted its holdings in Day One Biopharmaceuticals by 22.4% in the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after buying an additional 40,387 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Day One Biopharmaceuticals by 24.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after purchasing an additional 8,522 shares in the last quarter. TD Asset Management Inc raised its holdings in Day One Biopharmaceuticals by 100.0% in the third quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock worth $677,000 after purchasing an additional 27,598 shares during the period. Finally, Hennion & Walsh Asset Management Inc. boosted its position in shares of Day One Biopharmaceuticals by 89.5% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock worth $660,000 after purchasing an additional 25,414 shares in the last quarter. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.